Merck Statement Regarding CUBICIN® (daptomycin for injection) Patent Litigation

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. CHKP
5. CRWD
6. ON
7. HNGE
8. INSP
9. SPY
10. MRVL

Go back to Merck Statement Regarding CUBICIN® (daptomycin for injection) Patent Litigation

Merck (MRK) Provides Statement Regarding CUBICIN Patent Litigation

November 12, 2015 11:50 AM EST

Merck (NYSE: MRK), known as MSD outside the United States and Canada, issued the following statement regarding the decision of the U.S. Court of Appeals for the Federal Circuit. The decision validated the patent for CUBICIN® (daptomycin for injection) that expires on June 15, 2016, but... More